The present invention relates to a method for fabrication of an extracellular matrix-induced self-assembly and to fabrication of an artificial tissue using same. The method for fabrication of an extracellular matrix-induced self-assembly comprise the steps of: (a) decellularizing and powdering a tissue-derived extracellular matrix (ECM); and (b) adding the decellularized extracellular matrix powder to cells and culturing the cells to form a cell-extracellular matrix powder self-assembly. Accordingly, the self-assembly has characteristics similar to those of extracellular matrix tissues and can be fabricated into three-dimensional artificial tissues 1 cm or greater in size, thus finding advantageous applications as a cell therapy product and an artificial tissue implant.

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

[Problem] To provide a method for producing an artificial three-dimensional muscle tissue, said method enabling stable, efficient and easy production of a muscle tissue, and an artificial three-dimensional muscle tissue produced by this method. [Solution] A method for producing an artificial three-dimensional muscle tissue, said method comprising steps of (i) forming a three-dimensional muscle tissue precursor, which is configured from a first muscle tissue support, a second muscle tissue support and muscle cells, by linearly arranging the muscle cells on the first muscle tissue support in such a manner that the muscle cells are located close to the first muscle tissue support at one end of the line and close to the second muscle tissue support at the other end of the line, and (ii) culturing the three-dimensional muscle tissue precursor to give an artificial three-dimensional muscle tissue, and an artificial three-dimensional muscle tissue obtained by this method.

Described herein are regenerative approaches with tunable cell-cell and cell-matrix interactions to enhance the ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum, level of cell-cell and cell-matrix interaction.

The apparatuses described herein relate to preparation of a meat product. Apparatuses, systems comprising the apparatuses, and methods of making and use the systems and apparatuses are described herein. These are useful for controlling one or more of growth on and separation of a meat product from an enclosed substrate. The apparatuses and systems are configured to receive fluid and grow the meat product and/or separate the meat product from the substrate in a scalable manner.

The present description provides improved methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro. Also provided are isolated invitro cell populations, compositions, and systems comprising TEP cells produced in vitro. Compositions and systems of cell populations of thymic epithelial cells and subpopulations thereof, as well as cells formed during different stages of differentiation of PS cells into thymic epithelial cells and subpopulations thereof are provided.

Described herein is a human, cardiovascular platform for assessing cardiotoxicity of novel/existing chemotherapeutic agents that takes advantage of microfluidic organ chip systems to examine interaction between hiPSC-derived cardiovascular cells in an integrated system. Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and human induced pluripotent stem cell derived endothelial cells (hiPSC-ECs) can serve as an in-vitro platform for assessing disease pathology, including infectious disease, evaluate drug efficacy, toxicity, cardiotoxicity and cardioprotection. This includes evaluating VEGFR2/PDGFR-inhibiting tyrosine kinase inhibitors and drug efficacy in a viral infection model, including coronaviruses. They are scalable, functionally-active cell types that mimic the cells comprising the myocardium and systemic vasculature.

The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

Provided herein are a scaffold having a surface hyperboloid structure and its fabrication method and application. The scaffold has internally disposed with pores where each of the pores connects with each other and any point on a surface of each of the pores has the hyperboloid structure. Since the surface of the scaffold is smooth and stress concentration is thereby avoided, the scaffold can withstand a greater external force in the case of the same porosity. Moreover, since the pores inside the scaffold connect with each other, the scaffold has a better permeability to fluid and is more conducive to tissue ingrowth. In addition, the scaffold has a large internal surface area, rendering it feasible to subsequent surface treatment, such as film coating, to be carried out on the internal surface of the scaffold.